2012-10-10 01:10:26 - Recently published research from Global Markets Direct, "Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2012", is now available at Fast Market Research

Global Markets Direct's, 'Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL). Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.


Full Report Details at
-

www.fastmr.com/prod/468487_relapsed_refractory_chronic_lymphocyt ..


Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL).
* A review of the Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL).
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) Overview
Therapeutics Development
An Overview of Pipeline Products for Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL)
Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics under Development by Companies
Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics - Products under Development by Companies
Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Development
Abbott Laboratories
Santaris Pharma A/S
Pharmacyclics, Inc.
Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
navitoclax - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ibrutinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SPC-2996 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ABT-263 + Fludarabine + Cyclophosphamide + Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ABT-263 + Bendamustine + Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ABT-199 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Clofarabine + Cytarabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics - Drug Profile Updates
Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics - Dormant Products
Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=468487&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.